The earnings call reflects a positive sentiment overall. The strong growth in KIMMTRAK revenue, global expansion, and progress in clinical trials are significant highlights. However, there are some concerns regarding moderating growth expectations and increased operating expenses.

Company Guidance -

Q3 2025

During the Immunocore Q2 and first half 2025 earnings call, the company provided comprehensive guidance highlighting significant metrics across various aspects of its operations. Immunocore reported $192 million in KIMMTRAK revenue for the first half of 2025, marking a 32% year-over-year growth. The second quarter alone saw $98 million in net sales, with $64 million from the United States, a 15% increase from Q2 2024. In Europe, Q2 net revenue reached $33 million, reflecting a 115% year-on-year growth. The company continues to expand globally, with KIMMTRAK launched in 28 countries and approved in 39. Immunocore's clinical pipeline includes three Phase III trials, with the TEBE-AM study expected to complete enrollment by mid-2026. The company maintains a strong balance sheet with $883 million in cash and marketable securities, supporting its ongoing R&D investments and operational growth.

KIMMTRAK Revenue Growth

For the first half of 2025, Immunocore generated $192 million in KIMMTRAK revenue, representing a 32% growth year-over-year.

Global Expansion and Recognition

KIMMTRAK has been launched in 28 countries and approved in 39 globally. It received its fourth Prix Galien for Best Biotech Product.

Strong Balance Sheet

Immunocore has a strong balance sheet with $883 million in cash and marketable securities.

Phase III Trial Progress

Three Phase III trials in oncology are ongoing, with TEBE-AM on track to complete enrollment within the next 12 months.

Reduction in Net Loss

Net loss decreased from $36 million to $5 million as revenue grew more than operating expenses.

Immunocore Holdings (IMCR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IMCR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.23 / -	0.17	―	―	―
Aug 07, 2025	2025 (Q2)	-0.14 / -0.20	-0.23	13.04% (+0.03)
May 07, 2025	2025 (Q1)	-0.38 / 0.10	-0.49	120.41% (+0.59)	―	―
Feb 26, 2025	2024 (Q4)	-0.23 / -0.47	-0.4	-17.50% (-0.07)
Nov 06, 2024	2024 (Q3)	-0.34 / 0.17	0.049	246.94% (+0.12)	―	―
Aug 08, 2024	2024 (Q2)	-0.48 / -0.23	-0.369	37.67% (+0.14)
May 08, 2024	2024 (Q1)	-0.37 / -0.49	-0.43	-13.95% (-0.06)	―	―
Feb 28, 2024	2023 (Q4)	-0.25 / -0.40	-0.63	36.51% (+0.23)
Nov 07, 2023	2023 (Q3)	-0.35 / 0.05	0.137	-64.23% (-0.09)	―	―
Aug 10, 2023	2023 (Q2)	-0.39 / -0.37	-0.172	-114.53% (-0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IMCR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$32.10	$31.93	-0.53%
May 07, 2025	$28.06	$29.92	+6.63%
Feb 26, 2025	$29.21	$30.77	+5.34%
Nov 06, 2024	$32.99	$33.51	+1.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Immunocore Holdings (IMCR) report earnings?

Immunocore Holdings (IMCR) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Immunocore Holdings (IMCR) earnings time?

Immunocore Holdings (IMCR) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IMCR EPS forecast?

IMCR EPS forecast for the fiscal quarter 2025 (Q3) is -0.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing